Shots: The P-III FIDELIO-DKD study in CKD and T2D enrolled over 13,000 patients with early kidney damage and more advanced stages of kidney disease. The data were presented at the […]readmore
Tags : Inflammatory
Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to […]readmore
Biosimilars
Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory
Shots: The EMA’s CHMP has recommended marketing authorization of Amsparity, a biosimilar referencing AbbVie’s Humira Amsparity will be available in a 40 mg pre-filled syringe and pre-filled pen for adults […]readmore
Shots: Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment […]readmore